Pyrilutamide is a new chemical with a unique mechanism of action that could prove useful for those who have not received good results from other hair loss products. It is currently undergoing phase II clinical trials for androgenetic alopecia.
Buy pyrilutamide is a synthetic androgen receptor antagonist under development by Suzhou Kintor Pharmaceuticals, a clinical-stage biotechnology company that focuses on androgen receptor related diseases that lack effective treatments. It is also known by the code name KX-826.
What is pyrilutamide?
Pyrilutamide (also known as KX-826) is a new topical androgen receptor antagonist that is currently undergoing phase 2 clinical trials in both the US and China. It is a high-affinity, silent androgen receptor antagonist that does not decrease systemic androgen levels so it is unlikely to cause unwanted side effects like decreased libido or erectile dysfunction seen with oral 5-alpha reductase inhibitors.
In a recent press release, Kintor Pharmaceutical announced that the first patients had received dosing in the US phase 2 trial for male androgenetic alopecia. This randomized, double-blind, vehicle-controlled trial is designed to observe a change in non-vellus target area hair count over 6 months.
Kintor Pharmaceutical is a clinical-stage biotechnology company focused on developing small molecule therapeutics targeting androgen receptor related diseases including cancer, alopecia and other autoimmune conditions. They are headquartered in Suzhou, China and have research and development operations across Taiwan, Hong Kong, and the US. They are working on a number of projects including their lead candidate, Proxalutamide.
How does pyrilutamide work?
Pyrilutamide is an androgen receptor antagonist (a drug that blocks the binding of androgen to its receptor) and is undergoing clinical trials for alopecia. It is also known as KX-826 and has a similar structure to RU58841.
The drug works by blocking testosterone from being converted into Dihydrotestosterone (DHT) in the scalp. DHT binds to the androgen receptor and inhibits the hair growth cycle, leading to thinning and eventual hair loss. buy pyrilutamide from MV Supplements blocks DHT from binding with the androgen receptor, which allows the hair follicle to grow longer.
It is currently being tested in a phase 2 trial in China. If successful, it could be a great alternative to finasteride and dutasteride for men with MPB. Kintor Pharmaceuticals, who are developing the drug, have announced that they plan to begin a phase 3 trial next year (2021). This would be fantastic news if it turns out to be an effective MPB treatment. We will keep you updated on this as we learn more about the trial.
Does pyrilutamide have any side effects?
Pyrilutamide has shown promising results in the clinical trials it has completed so far.
The drug applied to the scalp once twice per day and blocks testosterone and DHT binding androgen receptors.
These results are very similar to those achieved by the hair loss drug finasteride. However, the main difference is that pyrilutamide does not decrease systemic androgen levels.This means that it is unlikely to cause the side effects seen in patients taking oral 5-alpha reductase inhibitors such as decreased libido and erectile dysfunction.
In a press release Kintor published this month,
the company announced that a phase 2 trial of pyrilutamide for male androgenic alopecia has begun in the US. This is a randomized, double-blind, placebo-controlled, vehicle-controlled clinical trial that will observe changes in target area hair count over a six-month period.
This is important milestone could lead pyrilutamide becoming the first topical anti-androgen approved for treatment of male pattern alopecia. You can see the complete drug development roadmap and progression for pyrilutamide (aka KX-826) in GlobalData’s Pyrilutamide LoA Report.
Where can I buy pyrilutamide?
Pyrilutamide (also known as KX-826) is a promising androgen receptor antagonist in development for treating androgenic alopecia.
It has a similar structure to RU58841 and is currently phase II clinical trials in both China and the US.
Pyrilutamide is a new compound and has not yet been marketed,
but it shows promising results with low side effects compared to oral 5-alpha reductase inhibitors.
PyriPure is a 0.5% pyrilutamide solution in an ethanol and propylene glycol vehicle.
Each batch of pyrilutamide is tested confirmed >99% pure by a professional testing before it is shipped customers.
This ensures the purity and quality of our pyrilutamide products.
Kintor Pharmaceutical is a clinical-stage company which discovers and develops small-molecule therapeutics.
The company focuses on the discovery of medicines that address androgen receptor-related diseases that lack effective treatments,
such as prostate cancer, breast cancer, hepatocellular carcinoma and leukaemia.The company carters to clients in Taiwan, Hong Kong,
the Us and Brazil. To learn more about Kintor Pharmaceutical, buy GlobalData’s Pyrilutamide LoA Report.
